Cancer-related innovation and U.S. patent applications
Alleamit Corporation, Minnesota, USA.
Review
International Journal of Scientific Research Updates, 2022, 04(02), 191–194.
Article DOI: 10.53430/ijsru.2022.4.2.0182
Publication history:
Received on 22 October 2022; revised on 22 November 2022; accepted on 25 November 2022
Abstract:
Cancer therapies bring hope to the suffering and dying patient. However, cancer research is complex and expensive. In addition, cancer is not just one disease but many. Each with its characteristics, risk factors, causes, and treatments—currently, 35 U.S. Code § 103 (obviousness) rejections are a rate-limiting step for acquiring a patent. Unfortunately, rejecting novel cancer-related patent applications based on obviousness inhibits funding for much-needed drug development and research.
Keywords:
Cancer; Drugs; Funding; Obviousness; Patents; Research
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0